A
Apellis Pharmaceuticals, Inc. (APLS)
NMS – Real Time Price. Currency in USD
41.06
+0.04 (0.10%)
At close: May 12, 2026, 4:00 PM EDT
41.06
0.00 (0.00%)
After-hours: May 12, 2026, 5:06 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
41.06
+0.04 (0.10%)
At close: May 12, 2026, 4:00 PM EDT
41.06
0.00 (0.00%)
After-hours: May 12, 2026, 5:06 PM EDT
No Data
There are no news for this stock.
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 3.63 | 6.05 | 10 | |
| Quick ratio | 3.16 | 5.63 | 10 | |
| Debt to Equity | 1.15 | 0.30 | 6.0 | |
| Debt to Assets | 0.44 | 1.04 | 5.0 | |
| Interest coverage | 2.57 | -16.91 | 7.0 | |
| Weighted average score | 7.6 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | 75M | 397M | 781M | 1B | 1.11B |
| Gross Profit | 68M | 336M | 664M | 902M | 996M |
| Operating Income | -595M | -517M | -165M | 55M | 165M |
| Net Income | -652M | -529M | -198M | 22M | 133M |
| EBITDA | -593M | -515M | -163M | 57M | 167M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | 16.65 | 5.56 | 7.0 |
| Next quarter | -52.22 | -115.74 | 1.0 |
| Current year | -13.6 | -639.94 | 1.0 |
| Next year | 18.36 | 89.92 | 9.5 |
| Weighted average score | 4.6 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 34.21 | 131.65 | -128.13 | -326.8 | 5.5 |
| Y/Y | 60.85 | 120.23 | -62.06 | -14.12 | 5.5 |
| 3y average | 183.77 | 64.27 | 68.06 | 73.54 | 10 |
| 5y average | 98.24 | 17.81 | 28.41 | -2.14 | 7.5 |
| Weighted average score | 7.1 | ||||
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |
Total debt $475.8M significantly exceeds cash reserves ($406.7M), raising financial stability concerns
Total current assets $1.0B exceed Total current liabilities $283.4M, highlighting excellent liquidity
Debt-to-equity ratio (1.1) is near the industry average, reflecting balanced leverage
Interest coverage ratio (3x) is sufficient but not particularly strong
Negative free cash flow -$61.0M limits the company's ability to reinvest or pay down debt